VCAR33AUTO is being studied in an ongoing Phase 1/2 clinical trial
sponsored by the National Marrow Donor Program (NMDP) in young adult and pediatric patients with relapsed/refractory AML in a bridge-to-transplant study.
We have received cross-reference rights for the IND for the NMDP program. Initial data from this study is expected in 2022, depending on the investigator’s timing of data release.
VCAR33AUTO Clinical Development
The NMDP is responsible for all aspects of this trial, including the design of the trial, the manufacture of study product, the enrollment, dosing and follow-up of patients, the recording of trial data and the analysis of results.
More information on this clinical trial can be found here.
*VCAR33AUTO is being studied in a Phase 1/2 clinical trial sponsored by the National Marrow Donor Program (“NMDP”), and timing of data release is dependent on the investigators conducting the trial. Although we are not the sponsor of this trial, the NMDP has permitted us to cross-reference its IND for this trial in future IND applications that we may submit with the FDA. For more information regarding the NMDP trial, see “Risk Factors – We have not successfully tested our product candidates in clinical trials and any favorable preclinical results are not predictive of results that may be observed in clinical trials” in our Annual Report on Form 10-K for the year ended December 31, 2021 filed with the SEC and such other filings that we may make with the SEC from time to time.